Yellowbird Diagnostics Completes Dosing inFirst-in-Human Phase 1 Trial of NeuCaVis™

Yellowbird Diagnostics Inc. recently announced the successful completion of dosing and imaging in its first-in-human Phase 1 clinical trial of NeuCaVis™, a novel F18 PET radiotracer designed to image inflammation. Led by Dr. Benjamin Chow, the study enrolled twelve healthy volunteers, including six men and six women, at the Ottawa Heart Institute. The trial is evaluating the safety, tolerability, biodistribution, and dosimetry of NeuCaVis™, while generating the first clinical data in humans.

Yellowbird Diagnostics is an OBIO® member, alumnus of our CAAP® program, and presented at the OBIO® Investment Summit.